Imaging Predictors of Treatment Response in Depression

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Helen Mayberg, Emory University
ClinicalTrials.gov Identifier:
NCT00367341
First received: August 18, 2006
Last updated: November 21, 2013
Last verified: November 2013
Results First Received: November 21, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Major Depressive Disorder
Interventions: Drug: escitalopram
Behavioral: Cognitive Behavioral Therapy (CBT)

  Participant Flow


  Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks   [ Time Frame: Measured at week 12 ]

2.  Secondary:   Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks   [ Time Frame: Measured at week 12. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information